HR-Positive and Triple-Negative Metastatic Breast Cancer — An Interview with Dr Laura Huppert on Optimal Integration of ADCs into Treatment
Breast Cancer Update
00:00
Will Dato‑DXd and SG compete in first‑line TNBC?
Dr Huppert anticipates upcoming trials comparing first‑line ADC strategies and that choice will depend on efficacy and toxicity.
Play episode from 17:53
Transcript
